4/14
07:11 am
cstl
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 [Yahoo! Finance]
Low
Report
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 [Yahoo! Finance]
4/14
07:00 am
cstl
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Low
Report
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
4/12
03:00 pm
cstl
The Melanoma Research Foundation to host the DC Miles for Melanoma 5K
Medium
Report
The Melanoma Research Foundation to host the DC Miles for Melanoma 5K
4/8
07:00 am
cstl
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Medium
Report
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
4/7
07:12 am
cstl
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year [Yahoo! Finance]
Medium
Report
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year [Yahoo! Finance]
4/7
07:00 am
cstl
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
Medium
Report
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
4/3
07:00 am
cstl
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
Medium
Report
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
4/1
04:30 pm
cstl
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
Low
Report
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
3/28
04:15 pm
cstl
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
Low
Report
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
3/28
08:02 am
cstl
Castle Biosciences, Inc. (NASDAQ: CSTL) was given a new $30.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.
Medium
Report
Castle Biosciences, Inc. (NASDAQ: CSTL) was given a new $30.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.
3/7
07:13 am
cstl
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio [Yahoo! Finance]
Low
Report
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio [Yahoo! Finance]
3/7
07:00 am
cstl
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
Medium
Report
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
3/1
07:07 pm
cstl
What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing? [Yahoo! Finance]
Medium
Report
What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing? [Yahoo! Finance]
2/28
09:20 am
cstl
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $36.00 to $37.00. They now have an "outperform" rating on the stock.
High
Report
Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target raised by analysts at Robert W. Baird from $36.00 to $37.00. They now have an "outperform" rating on the stock.
2/27
05:28 pm
cstl
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results [Yahoo! Finance]
High
Report
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results [Yahoo! Finance]
2/27
04:05 pm
cstl
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
High
Report
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
2/26
08:07 am
cstl
What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnings [Yahoo! Finance]
2/25
05:01 pm
cstl
Castle Biosciences to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Castle Biosciences to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/25
04:30 pm
cstl
Castle Biosciences to Participate in Upcoming Investor Conferences
Medium
Report
Castle Biosciences to Participate in Upcoming Investor Conferences
2/12
04:46 pm
cstl
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii® [Yahoo! Finance]
Low
Report
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii® [Yahoo! Finance]
2/12
04:30 pm
cstl
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
Low
Report
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
2/12
02:28 pm
cstl
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock [Yahoo! Finance]
Low
Report
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock [Yahoo! Finance]
2/6
07:14 am
cstl
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025 [Yahoo! Finance]
Low
Report
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025 [Yahoo! Finance]
2/6
07:00 am
cstl
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
Low
Report
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
2/2
05:11 am
cstl
Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss [Yahoo! Finance]
Medium
Report
Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss [Yahoo! Finance]